Amphastar Pharmaceuticals Share Price Raised to US$22

Published By : 24 Jun 2015 | Published By : QYRESEARCH

Research experts at BMO Capital Markets rose their target cost on shares of Amphastar Pharmaceuticals from US$20.00 to US$22.00 in a report discharged on Tuesday. BMO Capital Markets' value target would show a potential upside of 22.49% from the stocks past close. Shares of Amphastar Pharmaceuticals exchanged down 0.72% on Tuesday, hitting US$17.83. 41,163 shares of the organization's stock exchanged hands. Amphastar Pharmaceuticals has a 1-year low of US$6.67 and a 1-year high of US$18.07. The stock's 50-day moving normal is US$15 and its 200-day moving normal is US$14. The organization's business sector top is US$797.43 million. 

Amphastar Pharmaceuticals last produced its earnings information on Wednesday, May 13th. The organization reported US$0.01 EPS for the quarter, beating the accord appraisal of (US$0.17) by US$0.16. The organization had income of US$56.89 million for the quarter, contrasted with the agreement evaluation of US$45.87 million. The organization's income for the quarter was up 24.0% on a year-over-year premise. Investigators expect that Amphastar will report US$2.91 EPS for the present financial year. 

Various different firms have additionally as of late remarked on AMPH. Experts at Needham & Company LLC raised their value focus on shares of Amphastar Pharmaceuticals from US$17.00 to US$21.00 and gave the organization a "purchase" rating in an exploration note on Friday, June 19th. Experts at Zacks downsized shares of Amphastar Pharmaceuticals from an "in number purchase" rating to a "hold" rating in an exploration note on Monday, June 8th. 

Examiners at Raymond James started scope on shares of Amphastar Pharmaceuticals in an examination note on Wednesday, June 3rd. They set an "in number purchase" rating and a US$23.00 value focus on the stock. At long last, experts at Jefferies Group set a focus on shares of Amphastar Pharmaceuticals of US$19.00 value and gave the organization a "purchase" rating in an exploration note on Thursday, May 14th.
Back To Top